Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Liabilities (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Total Liabilities for 6 consecutive years, with $251.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 2.04% year-over-year to $251.1 million, compared with a TTM value of $251.1 million through Dec 2025, down 2.04%, and an annual FY2025 reading of $249.7 million, down 67.73% over the prior year.
  • Total Liabilities was $251.1 million for Q4 2025 at Roivant Sciences, down from $257.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $845.0 million in Q2 2022 and bottomed at -$2.4 billion in Q3 2021.
  • Average Total Liabilities over 5 years is $415.1 million, with a median of $576.6 million recorded in 2021.
  • The sharpest move saw Total Liabilities surged 128.88% in 2022, then tumbled 67.73% in 2025.
  • Year by year, Total Liabilities stood at $552.1 million in 2021, then skyrocketed by 40.52% to $775.8 million in 2022, then dropped by 6.15% to $728.1 million in 2023, then plummeted by 64.79% to $256.4 million in 2024, then dropped by 2.04% to $251.1 million in 2025.
  • Business Quant data shows Total Liabilities for ROIV at $251.1 million in Q4 2025, $257.1 million in Q3 2025, and $216.7 million in Q2 2025.